RxDoctor Payments DataLook up a doctor →

Allan Seibert, MD

Pulmonary Disease · Mobile, ALNPI 1801872353

Payments from drug & device makers

$2,363,919in general payments, 2019–2025

Across 333 payments — averaging $7098.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$994K
  • Gilead$588K
  • GSK$485K
  • Sanofi US Services Inc.$149K
  • Hoffmann-la Roche Limited$84K
  • AstraZeneca$42K
  • plus $23K from 21 others

What the payments were for

  • Food & beverage$3,11599%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,363,919 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$137,718
Medicare patients
265
Services billed
4,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter702$560,035
Breztri AerosphereBudesonide/Glycopyr/Formoterol176$145,355
OfevNintedanib Esylate11$138,967
Spiriva RespimatTiotropium Bromide141$87,071
Breo ElliptaFluticasone/Vilanterol142$71,734
Combivent RespimatIpratropium/Albuterol Sulfate52$33,047
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$32,019
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$26,705
EliquisApixaban34$24,348
SymbicortBudesonide/Formoterol Fumarate86$23,913
Albuterol Sulfate HfaAlbuterol Sulfate499$14,026
XareltoRivaroxaban14$11,515
Incruse ElliptaUmeclidinium Bromide24$8,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$7,183
Fluticasone Propionate HfaFluticasone Propionate17$6,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$485,472$677,790943 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$11,760$285,789244 claims
AstraZenecaBreztri Aerosphere, Symbicort$41,559$169,267262 claims
PfizerEliquis$1,011$24,34834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →